Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. This indicates that each pending matter is being handled by a different examiner in a separate administrative unit. The presence of 2 distinct art units suggests that the company's biotechnology research is being evaluated under different technical classifications.
BORALSKY, LUKE ALAN is the busiest examiner for this portfolio, with 1 pending office action. This count of 1 is compared to the 2 total pending office actions for the company. Because there are 2 distinct examiners for 2 actions, the workload is evenly split between the involved officials. For the practitioner, this means that there is no central examiner contact for the current portfolio, and each pending action follows its own unique prosecution trajectory within its respective art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282082 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | LEE, CHIHYI NMN | 36d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282082 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | LEE, CHIHYI NMN | 36d |
| 18697150 | QUINAZOLINE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BORALSKY, LUKE ALAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697150 | QUINAZOLINE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18282082 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | LEE, CHIHYI NMN | 1628 | §103§112 | Final Rejection | 36d | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial